All News
Drug Naming Games (2.7.2025)
Dr. Jack Cush reviews the news, regulatory and journal reports from the past week on RheumNow.com.
Read Article
ACR Commends Legislation Addressing Harmful Medicare Payment Cuts to Physicians
The American College of Rheumatology (ACR) applauded the bipartisan introduction of the Medicare Patient Access and Practice Stabilization Act of 2025, legislation to fully offset the harmful 2.8% cut in the Medicare Physician Fee Schedule (MPFS).
Read Article
Is Rheumatoid Arthritis Becoming Milder?
A 24 year, prospective study analyzing very early rheumatoid arthritis (RA) in three consecutive eras suggests that RA has evolved since 2005, demonstrating less seropositivity, inflammation, and erosions but is characterized by more comorbidity, smoking and corticosteroid use.
Read Article
Recent Excess Mortality in Young Adults
JAMA has published a University of Minnesota cross-sectional study showing early adult (ages 25-44) mortality in the U.S. has risen substantially between 2011 to 2019 and 2020 to 2023. The largest portion of 2023 excess mortality was driven by drug poisoning, but many other external and natural causes exceeded what prior trends would have projected.
Read Article
Young Males and Future Risk of MSK and Chronic Diseases
A large cohort of 18-year-old Swedish males were followed longitudinally for cardiovascular, respiratory, and musculoskeletal outcomes.
ACR Applauds Second Round of Medicare Drug Price Negotiations
The American College of Rheumatology applauded the announcement of additional drugs subject to pricing negotiations with the Centers for Medicare & Medicaid Services. This second round includes nintedanib (Ofev) and apremilast (Otezla), which are used to treat common and rare rheumatologic conditions.
Read Article
Adalimumab Withdrawal in Uveitis Patients
Adalimumab is an effective treatment for JIA-associated uveitis and has been FDA approved for such use - but for how long and can the drug be withdrawn? An adalimumab (ADA) withdrawal trial has shown recurrence of uveitis, arthritis, or both, when the disease was previously controlled on ADA.
Read Article
Weak Data (1.24.2025)
Dr. Jack Cush reviews the news and journal reports from RheumNow.com, and features Dr. Charity Dean, the Keynote speaker at RheumNow Live 2025, and why she is an inspiration.
Read Article
Getting to Remission - Without Biologics
Analysis of data from two early rheumatoid arthritis (ERA) cohorts shows remission in RA is primarily seen in those who do not require biologic DMARDs (bDMARDs), while those needing bDMARDs are less apt to achieve remission.
Do Rheumatologists Follow 2020 ACR Guidelines on Gout?
Schlessinger and colleagues report that US Rheumatologists generally adhere to and agree with the 2020 American College of Rheumatology (ACR) Guideline for the Management of Gout, although knowledge gaps and practice variance exists.
ACR: Congress Fails to Reform PBMs, Mitigate Medicare Cuts
The American College of Rheumatology (ACR) commended the limited extension of key Medicare telehealth coverage provisions but also expressed disappointment that Members of Congress have failed to pass measures to bring transparency to pharmacy benefit manager (PBM) practices, address flawed insur
Read Article
Screening for Osteoporosis to Prevent Fractures - USPSTF Recommendations
The US Preventive Services Task Force (USPSTF) has done a systematic review on osteoporosis screening to prevent fractures and put forth its recent recommendations.
Read Article
Alive in 2025 (1.10.2025)
Dr. Jack Cush brings in the new year with a review of the latest from RheumNow.com
Read Article
GLP-1 Agonists Alleviate Knee Osteoarthritis
In October, the NEJM published a randomized clinical trial demonstrating the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1ra) in patients with obesity and knee osteoarthritis.
Read Article
Does Colchicine Lower Gout Mortality Risk?
Data from a large UK database finds that gout patients starting urate-lowering therapy (ULT) will benefit from added colchicine prophylaxis by having fewer cardiovascular events.
Read Article
Prevalence of Autoimmune Diseases in the United States
An epidemiologic assessment of the prevalence of autoimmune diseases in the United States (US) finds that nearly 5% of the population has an autoimmune disorder, twice as many in women compared to men.
Read Article
ICYMI: VITAL Info on Autoimmune Disease (2.9.2024)
Dr. Jack Cush reviews the journal reports from the past week on RheumNow.com. Highlights are summarized by three songs: "Stairway to Heaven", "You're No Good", and "How Long (has this been going on)".
Read Article
Best of 2024: BSR Guidelines for Systemic Sclerosis Management
The British Society for Rheumatology has updated its 2015 guidelines for the management of patients with systemic sclerosis (SSc) based on published evidence, systematic literature review and expert opinion.
Read Article
Best of 2024: SGLT2 Inhibitor Protective Effects in Lupus
Systemic lupus erythematosus (SLE) outcomes were assessed based on whether they received sodium-glucose co-transporter 2 inhibitors (SGLT2i), in the setting of comorbid type 2 diabetes (T2D).
Read Article
